256 related articles for article (PubMed ID: 15454951)
21. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
[TBL] [Abstract][Full Text] [Related]
22. Progress toward the genetic treatment of the beta-thalassemias.
Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I
Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654
[TBL] [Abstract][Full Text] [Related]
23. Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns.
Laufs S; Nagy KZ; Giordano FA; Hotz-Wagenblatt A; Zeller WJ; Fruehauf S
Mol Ther; 2004 Nov; 10(5):874-81. PubMed ID: 15509505
[TBL] [Abstract][Full Text] [Related]
24. Toolbox for retrovectorologists.
Pagès JC; Bru T
J Gene Med; 2004 Feb; 6 Suppl 1():S67-82. PubMed ID: 14978752
[TBL] [Abstract][Full Text] [Related]
25. [General principles of the production and use of retroviral vectors].
Lehn P
Pathol Biol (Paris); 1993 Oct; 41(8):658-62. PubMed ID: 8290308
[TBL] [Abstract][Full Text] [Related]
26. Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.
Lamers CH; van Elzakker P; Luider BA; van Steenbergen SC; Sleijfer S; Debets R; Gratama JW
Cancer Gene Ther; 2008 Apr; 15(4):268-74. PubMed ID: 18202714
[TBL] [Abstract][Full Text] [Related]
27. A large preclinical animal model to assess ex vivo skin gene therapy applications.
Pfützner W; Joari MR; Foster RA; Vogel JC
Arch Dermatol Res; 2006 Jun; 298(1):16-22. PubMed ID: 16565820
[TBL] [Abstract][Full Text] [Related]
28. Genetic modification of hematopoietic cells using retroviral and lentiviral vectors: safety considerations for vector design and delivery into target cells.
Dropulic B
Curr Hematol Rep; 2005 Jul; 4(4):300-4. PubMed ID: 16009045
[TBL] [Abstract][Full Text] [Related]
29. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation.
Neschadim A; McCart JA; Keating A; Medin JA
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1407-16. PubMed ID: 18022569
[TBL] [Abstract][Full Text] [Related]
30. Gene therapy insertional mutagenesis insights.
Davé UP; Jenkins NA; Copeland NG
Science; 2004 Jan; 303(5656):333. PubMed ID: 14726584
[No Abstract] [Full Text] [Related]
31. Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches.
Brandtner EM; Kodajova P; Hlavaty J; Jandl G; Tabotta W; Salmons B; Günzburg WH; Hohenadl C
J Gene Med; 2008 Feb; 10(2):113-22. PubMed ID: 18076132
[TBL] [Abstract][Full Text] [Related]
32. Serial transplantations in nonobese diabetic/severe combined immunodeficiency mice of transduced human CD34+ cord blood cells: efficient oncoretroviral gene transfer and ex vivo expansion under serum-free conditions.
Gammaitoni L; Lucchi S; Bruno S; Tesio M; Gunetti M; Pignochino Y; Migliardi G; Lazzari L; Aglietta M; Rebulla P; Piacibello W
Stem Cells; 2006 May; 24(5):1201-12. PubMed ID: 16410386
[TBL] [Abstract][Full Text] [Related]
33. Looking into the safety of AAV vectors.
Kay MA; Nakai H
Nature; 2003 Jul; 424(6946):251. PubMed ID: 12867952
[No Abstract] [Full Text] [Related]
34. Lentiviral vectors: are they the future of animal transgenesis?
Park F
Physiol Genomics; 2007 Oct; 31(2):159-73. PubMed ID: 17684037
[TBL] [Abstract][Full Text] [Related]
35. Retroviral vector-mediated gene expression in hematopoietic cells.
Baum C; Richters A; Ostertag W
Curr Opin Mol Ther; 1999 Oct; 1(5):605-12. PubMed ID: 11249667
[TBL] [Abstract][Full Text] [Related]
36. Gene therapy resumes.
Novak K
Nat Rev Cancer; 2002 Nov; 2(11):813. PubMed ID: 12442759
[No Abstract] [Full Text] [Related]
37. Sonic hedgehog gene-enhanced tissue engineering for bone regeneration.
Edwards PC; Ruggiero S; Fantasia J; Burakoff R; Moorji SM; Paric E; Razzano P; Grande DA; Mason JM
Gene Ther; 2005 Jan; 12(1):75-86. PubMed ID: 15510177
[TBL] [Abstract][Full Text] [Related]
38. Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation.
Mostoslavsky G; Kotton DN; Fabian AJ; Gray JT; Lee JS; Mulligan RC
Mol Ther; 2005 Jun; 11(6):932-40. PubMed ID: 15922964
[TBL] [Abstract][Full Text] [Related]
39. Retroviral bicistronic vectors.
Pfützner W
Drug News Perspect; 2008 Nov; 21(9):473-80. PubMed ID: 19180265
[TBL] [Abstract][Full Text] [Related]
40. Clinical research. Gene therapy a suspect in leukemia-like disease.
Marshall E
Science; 2002 Oct; 298(5591):34-5. PubMed ID: 12364755
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
